EMA Decides Fast-Track Fate Of Masitinib And Anthrax Antitoxin

 
• By Neena Brizmohun
  
Bacteria
Anthrax antitoxin developer Elusys is one of two new companies seeking an accelerated assessment • Source: Shutterstock

More from Product Reviews

More from Pink Sheet